Ligand Pharmaceuticals

LGND

Market cap $3.22B

Overview Fund Activity

165.41 USD

-0.83

0.5%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

166.73

+1.32

0.8%

1 day

-0.5%

5 days

-0.86%

1 month

7.93%

3 months

46.98%

6 months

50.44%

Year to date

52.56%

1 year

58.65%

5 years

181.64%

10 years

160.78%

About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Employees: 68

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

10,027% more call options, than puts

Call options by funds: $1.11M | Put options by funds: $11K

300% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 4 (+3) [Q2]

52% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 23

31% more repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 84

11% more capital invested

Capital invested by funds: $1.97B [Q1] → $2.18B (+$215M) [Q2]

4% more funds holding

Funds holding: 258 [Q1] → 268 (+10) [Q2]

2.47% more ownership

Funds ownership: 96.96% [Q1] → 99.43% (+2.47%) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$175

6% upside

Avg. target

$189

14% upside

High target

$206

25% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Trevor Allred	$190	Outperform Maintained	3 Sep 2025
Benchmark Robert Wasserman	$175	Buy Maintained	2 Sep 2025
HC Wainwright & Co. Joseph Pantginis	$206	Buy Maintained	28 Aug 2025
RBC Capital Douglas Miehm	$185	Outperform Maintained	8 Aug 2025

See Analyst Rankings

Financial journalist opinion

Ligand to Participate in September Investor Conferences

JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m.

Ligand to Participate in September Investor Conferences

Ligand Announces Closing of Convertible Senior Notes Offering

JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible senior notes due 2030 (the “notes”).

Ligand Announces Closing of Convertible Senior Notes Offering

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030

JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors.

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030

Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Lauren Hay - Corporate Participant Melanie Herman - Corporate Participant Octavio Espinoza - Chief Financial Officer Paul J. Hadden - Senior Vice President of Investments & Business Development Todd C.

Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript

The Motley Fool

Ligand (LGND) Q2 Revenue Jumps 15%

Ligand Pharmaceuticals (LGND -0.34%), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7, 2025. The company exceeded analyst estimates with non-GAAP EPS of $1.60 (consensus: $1.42) and reported revenue of $47.6 million (consensus: $43.87 million) for the second quarter.

Ligand (LGND) Q2 Revenue Jumps 15%

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share 1 increased to $6.70 - $7.00 (previously $6.00 - $6.25) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private placement and an additional $20 million in a secured subordinated promissory note convertible to prepaid revenue share • Medtronic and Orchestra BioMed expand strategic collaboration to provide pathway for development of AVIM therapy-enabled leadless pacemakers NEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the Company has secured $70 million in new capital from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND, “Ligand”) and Medtronic, plc.

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025.

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum.

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

See News Rankings

Charts implemented using Lightweight Charts™